咪唑并[1,2-a]吡啶-7-甲酸乙酯 | 372147-49-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 咪唑并[1,2-a]吡啶-7-甲酸乙酯
• 中文别名: 咪唑并[1,2-a]吡啶-7-羧酸乙酯；咪唑并[1,2-A]砒啶-7-羧酸乙酯
• 英文名称: ethyl imidazo[1,2-a]pyridine-7-carboxylate
• CAS: 372147-49-4
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD08436046
• 分子量: 190.202
• InChiKey: UWYWNAGXCZHLLM-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  请保持冷态。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl imidazo[1,2-a]pyridine-7-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl imidazo[1,2-a]pyridine-7-carboxylate
CAS number: 372147-49-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10N2O2
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  咪唑并[1,2-A]吡啶-7-碳酰肼	imidazo[1,2-a]pyridine-7-carbohydrazide	421595-78-0	C8H8N4O	176.178
  咪唑并[1,2-a]吡啶-7-羰基叠氮化物	Imidazo[1,2-a]pyridine-7-carbonyl azide	421595-79-1	C8H5N5O	187.161

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  咪唑并[1,2-a]吡啶-7-甲醛	imidazo[1,2-a]pyridine-7-carbaldehyde	136117-73-2	C8H6N2O	146.148
  咪唑并[1,2-a]吡啶-7-甲醇	imidazo[1,2-a]pyridin-7-ylmethanol	342613-80-3	C8H8N2O	148.164
  ——	imidazor[1,2-a]pyridine-7-carboxylic acid amide	1036990-69-8	C8H7N3O	161.163
  咪唑并[1,2-A]吡啶-7-碳酰肼	imidazo[1,2-a]pyridine-7-carbohydrazide	421595-78-0	C8H8N4O	176.178
  ——	imidazo[1,2-a]pyridin-7-ylmethanamine	1073428-81-5	C8H9N3	147.18
  咪唑并[1,2-a]吡啶-7-羰基叠氮化物	Imidazo[1,2-a]pyridine-7-carbonyl azide	421595-79-1	C8H5N5O	187.161
  ——	7-(azidomethyl)imidazo[1,2-a]pyridine	1186518-67-1	C8H7N5	173.177

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-a]吡啶-7-甲酸乙酯 在 盐酸 、 sodium hydroxide 、 一水合肼 、 sodium nitrite 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 79.67h， 生成 N-(triphenyl-λ⁵-phosphanylidene)imidazo[1,2-a]pyridin-7-amine
  参考文献：
  名称：

  Aminoimidazo[1,2-a]pyridines: regioselective synthesis of substituted imidazonaphthyridines, azacarbolines and cyclazines

  摘要：

  In order to study the regioselectivity of thermal cyclocondensation, aminoimidazo [1,2-a]pyridines (AIP) 5a-e were prepared, further converted into iminophosphoranes 7a-e, and ultimately converted regioselectively in angular annulated imidazonaphthyridines (IN) 8a, 10a, 11a, 12a or linear annulated dipyridoimidazole (DPI) 17a. From 2-substituted derivative 23, the peri annulated product 24a was obtained. The starting amines 5a-f reacted with aldehydes to yield regioselectively IN 8a-c, 10a-c, 11a-c, 12a,b, DPI 16a-e, 17a-d and TIBO like structures (+/-)-13 and 24a-c, as proved by X-ray analysis. The 1,2- or 1,4-addition between amines and alpha,beta-unsaturated aldehydes concerning the pyridine and imidazole moieties is discussed in the light of these results. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(01)01141-3
• 作为产物：
  描述：

  咪唑并[1,2-A]吡啶-7-碳酰肼 在 盐酸 、 sodium nitrite 作用下， 反应 6.5h， 生成 咪唑并[1,2-a]吡啶-7-甲酸乙酯
  参考文献：
  名称：

  Aminoimidazo[1,2-a]pyridines: regioselective synthesis of substituted imidazonaphthyridines, azacarbolines and cyclazines

  摘要：

  In order to study the regioselectivity of thermal cyclocondensation, aminoimidazo [1,2-a]pyridines (AIP) 5a-e were prepared, further converted into iminophosphoranes 7a-e, and ultimately converted regioselectively in angular annulated imidazonaphthyridines (IN) 8a, 10a, 11a, 12a or linear annulated dipyridoimidazole (DPI) 17a. From 2-substituted derivative 23, the peri annulated product 24a was obtained. The starting amines 5a-f reacted with aldehydes to yield regioselectively IN 8a-c, 10a-c, 11a-c, 12a,b, DPI 16a-e, 17a-d and TIBO like structures (+/-)-13 and 24a-c, as proved by X-ray analysis. The 1,2- or 1,4-addition between amines and alpha,beta-unsaturated aldehydes concerning the pyridine and imidazole moieties is discussed in the light of these results. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(01)01141-3

文献信息

• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009047506A1

  公开（公告）日：2009-04-16

  The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及公式（I）的新的双环杂环衍生物化合物，其中R1、A、X1、X2、X3、X4、X5和R2如本文所定义，以及包含该化合物的药物组合物，以及该化合物在治疗疾病（例如癌症）中的用途。
• Heterocyclization of Functionalized Vinylic Derivatives of Imidazo[1,2-<i>a</i>]pyridines
  作者：Jean M. Chezal、Emmanuel Moreau、Gregory Delmas、Alain Gueiffier、Yves Blache、Gérard Grassy、Claire Lartigue、Olivier Chavignon、Jean C. Teulade

  DOI：10.1021/jo015582x

  日期：2001.10.1

  functionalized vinylic derivatives of imidazo[1,2-a]pyridines was explored experimentally and theoretically using semiempirical AM1 and ab initio methods. A range of functionalized vinylic derivatives (azido, amino, and carbodiimide groups) were prepared for conversion into pyrroloazaindoles 19-22, imidazo[1,x]-, (x = 5, 6, 7, 8), [2,6]-, and [2,7]naphthyridines 28-30, 35-38 by thermal reaction. In the case

  咪唑并[1,2-a]吡啶的官能化乙烯基衍生物的杂环化使用半经验AM1和从头算的方法在理论上进行了探索。制备了一系列官能化的乙烯基衍生物（叠氮基，氨基和碳二亚胺基团），用于转化为吡咯并氮杂吲哚19-22，咪唑并[1，x]-，（x = 5、6、7、8），[2,6] -和[2,7]萘啶28-30、35-38通过热反应。在乙烯基位于5位的情况下，还观察到围成环。对实验和理论数据进行了比较和讨论。
• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES UTILISÉS COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009047522A1

  公开（公告）日：2009-04-16

  The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, q, A, B, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  该发明涉及公式（I）的新的双环杂环衍生物化合物，其中R1、q、A、B、X1、X2、X3、X4、X5和R2如本文所定义，以及包含该化合物的药物组合物，以及该化合物在治疗疾病（例如癌症）中的用途。
• [EN] ANTIFUNGAL AGENTS<br/>[FR] AGENTS ANTIFONGIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010019204A1

  公开（公告）日：2010-02-18

  Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs,,as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

  本文披露了恩富马富金的新颖衍生物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物、制备这些化合物的方法以及将这些化合物用作抗真菌剂和/或（1,3）-β-D-葡聚糖合酶抑制剂的方法。所披露的化合物、它们的药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗和/或预防真菌感染及相关疾病和症状。
• Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4
  作者：Delphine Charvin、Vincent Pomel、Millan Ortiz、Mélanie Frauli、Sophie Scheffler、Edith Steinberg、Luc Baron、Laurène Deshons、Rachel Rudigier、Delphine Thiarc、Christophe Morice、Baptiste Manteau、Stanislas Mayer、Danielle Graham、Bruno Giethlen、Nadia Brugger、Gaël Hédou、François Conquet、Stephan Schann

  DOI：10.1021/acs.jmedchem.7b00991

  日期：2017.10.26

  The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its therapeutic potential, no ligand has been successfully developed enough to be tested in the clinic. In the present paper, we report for the first time the medicinal chemistry efforts conducted around the pharmacological tool (−)-PHCCC. This work led

  代谢型谷氨酸受体4（mGluR4）是治疗帕金森氏病（PD）的新兴靶标。然而，自发现其治疗潜力以来，没有成功开发出足以在临床上进行测试的配体。在本文中，我们首次报告了围绕药理学工具（-）-PHCCC进行的药物化学研究。这项工作导致了化合物40的鉴定，一种有效的，选择性的mGluR4阳性变构调节剂（PAM），具有良好的水溶性，并在腹膜内给药后在经过验证的PD运动症状的临床前啮齿动物模型中表现出一致的活性：氟哌啶醇在小鼠和大鼠中引起的僵直和6-羟基多巴胺（6-OHDA）病变模型。此外，我们还描述了口服给药后化合物60与化合物40的紧密类似物具有改善的药代动力学特征的鉴定。基于其有利和独特的临床前特性，化合物60（PXT002331，现为foliglurax）被提名为临床开发的候选药物。